Looking Beyond DNA to See Cancer with New Clarity

Mapping How Mutated Proteins Interact Reveals Previously Unseen Cancer Targets

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) — Researchers at UC San Francisco and UC San Diego have mapped out how hundreds of mutations involved in two types of cancer affect the activity of proteins that are the ultimate actors behind the disease. The work points the way to identifying new precision treatments that may skirt side effects common with much current chemotherapy.

The effort, dubbed Cancer Cell Mapping Initiative (CCMI), is led by Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute and Trey Ideker, PhD, professor at University of California San Diego School of Medicine and Moores Cancer Center, who are also co-senior authors on a set of three related studies that describe the map. The papers appear September 30 in Science.

“This is an entirely new way to do cancer research,” said Nevan Krogan. Krogan noted that targeted treatments based simply on DNA sequencing of tumors haven’t been as effective as hoped. “We realized we need another way to look at cancer that takes it a step beyond DNA.”

“The bottom line is that we’re elevating the conversation about cancer from individual genes to whole protein complexes,” Ideker said. “For years different groups have been discovering more and more gene mutations that are involved in cancers. But now we’re able to explain these mutations at the next level — by looking at how the different gene mutations in different patients actually have the same downstream effects on the same protein machines. This is the first map of cancer from the protein complex lens.”

Looking Beyond Gene Mutations to the Protein Disruptions They Cause

The team looked at proteins, which carry out the vast majority of functions in the body—and which take on a collection of forms that far outnumber our genes, providing a much more expansive view of the activity underlying cancer.

DNA contains the instructions for building proteins, which then interact with other proteins, almost always in large groups called complexes. These protein complexes regulate an activity or turn a function on or off. If the underlying DNA has a mutation, the resulting protein complexes will as well.

These gene mutations can affect how well the resulting protein complexes do their jobs. For example, a particular interaction between two proteins might be crucial to repairing damaged DNA. If the mutated version of one of those proteins is shaped differently than normal, it may not interact correctly with the other protein, and the DNA might not get repaired, leading to cancer.

Mapping Protein Mutations

There is a subset of genes that are commonly mutated in cancer, Krogan said, and each of these genes can be mutated in hundreds of different ways. In addition, the function of a particular protein may be different in different types of cells, so a mutation in a breast cancer cell might have different effects on protein complexes than that same mutation’s effect in a cell in the throat.

CCMI’s goal was to map the constellation of protein complexes formed by approximately 60 proteins commonly involved in either breast cancer and cancers of the head and neck, and to see what each looked like in healthy cells. Alongside that effort, they created maps of how protein complexes are affected by hundreds of different gene mutations in two cancerous cell lines.

Doing so presented a formidable computational challenge. But the CCMI collaboration allowed the team to use advanced and novel data analyses to reveal not only whether the mutation affected interactions between proteins, but to what extent.

“That kind of detail shows us how well an existing drug might work, or explains why it doesn’t,” Ideker said.

The most powerful aspect of these extensive protein interaction maps is that they can shed the same light on many other conditions, Krogan said. For example, the team is also at work on similar studies of protein interactions in psychiatric and neurodegenerative disorders, as well as infectious disease.

Collaboration is Key

Krogan and Ideker see the CCMI collaboration as the real source of strength behind the approach.

“We’re not only making connections between different genes and proteins but between different people and different disciplines,” Krogan said. “Those collaborations have built up an infrastructure that allows them to integrate an array of types of information and push the boundaries of what’s possible in applying data science to complex diseases.”

“We’re in the perfect position to take advantage of this revolution on every level. I couldn’t be more excited than I am right now. We can do such damage to cancer.”

Funding: This research was supported by grants from the National Cancer Institute (U54 CA209891, U54 CA209988, 5F30CA236404-02) and the National institutes of Health (F32 CA239336, R50 CA243885, S10 OD026929) as well as other public and philanthropic sources.

About QBI: The Quantitative Biosciences Institute (QBI) fosters collaborations across the biomedical and the physical sciences, seeking quantitative methods to address pressing problems in biology and biomedicine. Motivated by problems of human disease, QBI is committed to investigating fundamental biological mechanisms, because ultimately solutions to many diseases have been revealed by unexpected discoveries in the basic sciences.

Follow UCSF
qbi.ucsf.edu | Facebook.com/qbiucsf | Twitter.com/qbi_ucsf | YouTube.com/qbitvucsf

About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu or see our Fact Sheet.

Follow UCSF
ucsf.edu | Facebook.com/ucsf | Twitter.com/ucsf | YouTube.com/ucsf

Media contacts:

Gina Nguyen, 646-326-8936
GinaT.Nguyen@ucsf.edu | @QBI_UCSF

Robin Marks, 415-663-6768
Robin.Marks@ucsf.edu | @UCSF

Heather Buschman, 858-249-0456
hbuschman@health.ucsd.edu | @UCSDMedSchool

Videos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/ff38e633-ed60-481f-8b22-a0f73929a7a9

https://www.globenewswire.com/NewsRoom/AttachmentNg/20119a6f-0bbc-42aa-aa8f-adc435b88697

SafeAI Welcomes Automotive Veteran Roger Nielsen to Board of Directors

Former Daimler Trucks CEO and autonomy pioneer brings nearly 40 years of experience in the commercial vehicle industry to SafeAI

MILPITAS, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) — SafeAI, a global leader in autonomous heavy equipment, today announced that Roger Nielsen has joined its Board of Directors. Nielsen, the former President and CEO of Daimler Trucks North America and member of the Board of Management of Daimler Truck AG, brings nearly forty years of experience in the commercial vehicle industry to SafeAI’s growing company.

Nielsen spent 35 years at Daimler, the world’s leading commercial vehicle manufacturer, including four years as President and CEO of Daimler Trucks North America. During his tenure, he was involved in 40 acquisitions, mergers and divestitures across the automotive industry, including companies developing buses, telematics, electric vehicles and autonomous driving systems.

During Nielsen’s time at Daimler, electric and autonomous vehicles began rapidly gaining steam. As CEO, he spearheaded significant advancements in Daimler’s autonomous technology to meet rising demand across the trucking industry, including through the acquisition of vehicle automation company Torc Robotics. Under his leadership, Daimler’s Advanced Driver Assistance Systems (ADAS) won Best Transportation Technology at the 2019 Consumer Electronics Show (CES) for its Level 2 automated driving system. The company went on to become the first to deliver SAE level 2 (partially automated driving features) into series production and today, continues to forge a safer, more efficient standard for logistics.

“Roger was at the helm of one of the world’s top automotive companies as the tides began turning toward autonomous vehicles. He quickly recognized the opportunity and dove in headfirst to unlock the benefits of autonomy for the trucking industry,” said Bibhrajit Halder, founder and CEO of SafeAI. “His experience as a trailblazer in autonomous development and deployment is an invaluable asset to our board as we reimagine heavy industry through increased adoption of self-driving heavy equipment.”

“At Daimler, I had the opportunity to lead a team rethinking a more traditional industry, logistics, through autonomous technology. As a member of SafeAI’s board, I’m fortunate to have that opportunity again,” said Nielsen. “I firmly believe autonomy is the future, and SafeAI will be the company to deliver this future to heavy industry. I’m honored to be part of this team as they chart a new path forward for industries like construction and mining, powered by autonomy.”

Nielsen received his BS in Industrial Engineering from Oregon State University. He is also on the board of NODAR, a company that develops 3D vision for autonomous vehicles.

For more news from SafeAI, visit www.safeai.ai.

About SafeAI
SafeAI is a global autonomous heavy equipment leader focused on advancing modern industry. SafeAI retrofits heavy equipment for autonomous applications in mining and construction to serve a massive ecosystem of industry players with complex needs. By building a software platform with the most advanced, industry-specific AI, SafeAI enables equipment owners to transform existing machines, including skid steers, F-150s and articulated dump trucks, into self-operating robotic assets. SafeAI is based in Milpitas, CA.

Contact
LaunchSquad for SafeAI
safeai@launchsquad.com

Virtusa Accelerates the Modernization and Personalization of Patient Care

vLife™ 6.0 Application Marketplace for Healthcare and Life Sciences

SOUTHBOROUGH, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) — Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions, today announced vLife™ 6.0, a cloud-based marketplace designed to improve and personalize patient care.

vLife™ 6.0 brings together previously inaccessible data with artificial intelligence (AI) applications, machine learning (ML) models, and industry-specific solutions – accessed via a self-service portal. vLife™ was developed in collaboration with leading universities and healthcare providers and has proven to accelerate the personalization of patient care.

The U.S. healthcare system alone generates approximately one trillion gigabytes of data annually. vLife™ 6.0 gives payers, providers, and medical device and life sciences companies the ability to capture, share and deliver data in a more unified way, which can increase productivity by approximately 30 percent.

Automating everything from data entry to medicine distribution and research analysis gives doctors and nurses the resources and the additional time needed to provide the best-personalized, quality care to each patient. By using AI tools and applications available in the vLife™ marketplace, healthcare providers can reduce diagnostic errors and provide the most up-to-date research and resources to support decision-making.

According to Business Insider Intelligence, 30 percent of healthcare costs are associated with administrative tasks. With the right solutions in place, organizations can automate administrative tasks, ease workflows, and analyze large data sets to deliver better healthcare faster, and at a lower cost. Among the key new features in vLife™ 6.0 is vNet, an enterprise AI application for building faster, smarter, and better ML models for harnessing all data.

By taking advantage of vLife™ 6.0, users can quickly start using pre-trained ML models, snippets of code, and accelerators to address specific healthcare-related tasks or functions.

“Healthcare and life sciences organizations need to access previously untapped patient data to drive operational efficiency, enhance the patient/provider experience, and ultimately provide more effective patient care,” said Anthony Lange, Senior Vice President, Healthcare and Life Sciences, Virtusa. “With vLife™ 6.0, we’re making it possible to quickly assemble and roll out pre-built models, applications and solutions designed by and with industry experts and digital engineers.”

ML applications can potentially improve the accuracy of treatment protocols and health outcomes through algorithmic processes. For example, deep learning, a type of complex ML that mimics how the human brain functions, is increasingly being used in radiology and medical imaging. Using neural networks that can learn from data without any supervision, deep learning applications can detect, recognize and analyze cancerous lesions from images.

Today physicians spend too much time using EHR—According to a 2020 Annals of Internal Medicine study, Physicians spent an average of 16 minutes and 14 seconds per encounter using EHRs. vLife™ 6.0 has applications to identify documentation gaps and prepopulate problem lists, enabling physicians to spend more valuable time with patients and less time at the computer.

Built on Amazon Web Services (AWS), vLife™ 6.0 provides access to the following:

  • One billion rows of clinical, claims, genomic and IBM MarketScan research data as well as simulated data for the full U.S. population across 34 disease conditions.
  • One thousand AI artifacts for partners to build ML models based on their organizational priorities and project budget.
  • Industry solutions designed to address specific challenges, functions or tasks.

vLife™ includes specialized offerings for key segments, including:

  • Biopharma: Clinical trials, Commercial analytics, Patient engagement, Bioinformatics-as-a-Service (BaaS)
  • MedTech: Commercial solutions, Connected solutions, Patient engagement, Provider and patient engagement
  • Payer services: Member journey, Claims processing, Care management, Provider journey
  • Provider services: Population Health Management (PHM), Patient engagement, Ancillaries, Virtual care, Advanced analytics

Key features and benefits of vNet:

  • Faster AI: An intuitive AI tool that enables users with no AI coding skills to easily build, train, and deploy ML models, all in one place, without writing a single line of code. Faster AI empowers teams to operationalize AI and drive business value.
  • Computer Vision: No-code/low-code image analytics platform that allows beginners to get started quickly and AI experts to develop faster and leverage custom code with a fully managed infrastructure for computer vision.
  • Synthetic Data: Uses algorithms to create artificial data by mirroring the statistical properties of the original data while allowing business to maintain user privacy, successfully carry out product testing, and train ML algorithms
  • Innovation as a Service (IaaS): Connects every step of the domain journey and hosts several solutions to help customers efficiently improve the cognitive system of the domain systems across various AI-driven innovations.

With personalization at the center of a new age of healthcare, patients will be able to reach new levels of health and wellness, while allowing providers to operate more efficiently and effectively. vLife™ 6.0 paves the way for the future of healthcare and patient care.

To learn more about vLife™, visit www.virtusa.com/vlife

About Virtusa

Virtusa Corporation is a global provider of digital business strategy, digital engineering, and information technology (IT) services and solutions that help clients change, disrupt, and unlock new value through innovation engineering. Virtusa serves Global 2000 companies in the Banking, Financial Services, Insurance, Healthcare, Communications, Media, Entertainment, Travel, Manufacturing, and Technology industries.

Virtusa helps clients grow their business with innovative products and services that create operational efficiency using digital labor, future-proof operational and IT platforms, and rationalization and modernization of IT applications infrastructure. This is achieved through a unique approach blending deep contextual expertise, empowered agile teams, and measurably better engineering to create holistic solutions that drive business forward at unparalleled velocity enabled by a culture of cooperative disruption.

Virtusa is registered trademark of Virtusa Corporation. All other company and brand names may be trademarks or service marks of their respective holders.

Contact:

Matt Berry
Conversion Marketing
(201) 370-9133
matt@conversionam.com

Modelo, the New Official Beer Sponsor of the College Football Playoff, Rewards the Fighting Spirit of College Football Fans With the New Unlockzie

The Unlockzie, a beer can cooler with image recognition technology, will offer fans the chance to unlock entries for prizes throughout the season

Modelo Unlockzie

Modelo is unveiling the Unlockzie, a free beer can cooler with technology that allows fans to unlock entries for prizes throughout the college football season.

CHICAGO, Sept. 30, 2021 (GLOBE NEWSWIRE) — College football is back in full swing and Modelo, the beer brewed for those with The Fighting Spirit™, is rewarding passionate fans across the country with a brand-new offering. To ensure all fans have a cold beer for game day Saturdays, Modelo is unveiling the Unlockzie, a free beer can cooler with technology that allows fans to unlock entries for prizes throughout the college football season.

The Unlockzie features a specially-designed seal and a unique cutout that completes a scannable image when a 12 oz. can of Modelo Especial is placed inside the beer can cooler. Fans will be able to scan this completed image on their mobile device using image recognition technology, giving them the opportunity to unlock entries for prizes each week.

The grand prize for one lucky fan is any college football lover’s dream—two tickets to the College Football Playoff National Championship on January 10, 2022. Each week, fans will be able to enter for a chance to win a weekly prize including a year’s worth of Modelo beer (awarded in the form of a $300 Sponsor-specified gift card) and Modelo swag.

This season, Modelo has entered a multi-year partnership as the Official Beer Sponsor of the College Football Playoff. As part of the sponsorship, Modelo will have rights to the College Football Playoff (CFP) marks/IP and marketing exclusivity on-site within CFP National Championship weekend events and New Year’s Six games.

“The Modelo Unlockzie provides an engaging way for fans to amplify their football experience while supporting their team with a cold Modelo in hand,” said Greg Gallagher, Vice President of Brand Marketing, Modelo. “Joining the roster as Official Beer Sponsor of the College Football Playoff is an opportunity to build our football fanbase and create a lasting Modelo connection with drinkers who bring their unique fighting spirt to each and every game day.”

The Unlockzie is available for free while supplies last at ModeloUnlockzie.com, and fans should follow @ModeloUSA on Instagram and Twitter throughout the regular college football season for news on when more Unlockzies will be released. See here for assets.

How it works:

  • Simply slide a 12 oz. can of Modelo Especial into the Unlockzie and line up the Modelo seal on the can with the opening.
  • Visit ModeloUnlockzie.com and scan the completed Unlockzie image to enter for a chance to win weekly a prize and to be entered into the grand prize drawing.
  • The Unlockzie can be scanned with a Modelo can every week during the Promotion Period to enter for a chance to win.

NO PURCHASE NECESSARY. The Modelo Beverage Can Holder Giveaway is open only to legal residents of the 50 U.S. and D.C., 21 or older, with a web-enabled mobile device; the Giveaway starts 10:00 AM ET on 9/30/21 and ends 11:59 PM ET on 12/4/21, or when the last fifteen thousand (15,000) entrants have been confirmed for the last Entry Period (as described in the Official Giveaway Rules, whichever occurs first). The Modelo Unlockzie Sweepstakes is open only to legal residents of the 50 U.S. and D.C., 21 or older; the Sweepstakes starts 10:00 AM ET on 9/30/21 and ends 11:59 PM ET on 12/4/21. No alcohol awarded with prizes. Void where prohibited. For complete details, see Official Rules at ModeloUnlockzie.com.

ABOUT MODELO®
Born in 1925 in the small town of Tacuba, Mexico, Modelo has been bringing distinctive high-quality beer to people ever since, including Modelo Especial®, Modelo Negra®, and a flavorful lineup of Modelo Cheladas. Modelo Especial is a golden, full-flavored Pilsner-style Lager with a clean, crisp finish. As the #1 imported beer in the U.S., Modelo Especial recently surpassed 150MM cases sold in 2021. The Modelo family of beers are exclusively brewed, imported and marketed for the U.S. by Constellation Brands.

ABOUT THE COLLEGE FOOTBALL PLAYOFF
The College Football Playoff matches the No. 1 ranked team vs. No. 4, and No. 2 vs. No. 3 in semifinal games that rotate annually among six bowl games – the Goodyear Cotton Bowl Classic, PlayStation Fiesta Bowl, Chick-fil-A Peach Bowl, Capital One Orange Bowl, Allstate Sugar Bowl and Rose Bowl Game. This season’s Playoff Semifinals will take place Friday, December 31, 2021, at the Cotton Bowl and Orange Bowl. The College Football Playoff National Championship will be Monday, January 10, 2022, at Lucas Oil Stadium in Indianapolis, Indiana.

Contact:
Kevin Hyde
kevin.hyde@ketchum.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/451183d3-3683-4ace-ba52-cea677d97496

Lankenau Heart Institute, part of Main Line Health, first in North America to sign long-term strategic partnership with Philips utilizing integrated cardiovascular solutions

September 30, 2021

Unique five-year agreement will help Philadelphia-based health leader integrate and standardize innovative cardiovascular care, helping to deliver on the quadruple aim

Amsterdam, the Netherlands and Philadelphia, PA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Lankenau Heart Institute part of Main Line Health, today announced they have entered a five-year strategic partnership focused on integrated cardiovascular solutions. Working together, Philips and Main Line Health will develop an ecosystem of clinically-enabled cardiovascular solutions that will allow Main Line Health to standardize and integrate technology across its network, helping to unlock patient data for better clinical decisions, while optimizing workflows for a better patient and staff experience. In addition, the partnership aims to help Main Line Health drive predictability and consistency in costs, as well as focus on clinical and technical training.

Providing care to the Philadelphia region and its western suburbs, Main Line Health is committed to delivering advanced medicine to treat and cure disease, while also playing an important role in prevention strategies and disease management. At its core are four of the region’s most respected acute care hospitals – Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital. Moreover, Main Line Health conducts clinical research in the latest health care innovations and trains physicians and other health care providers to ensure its staff can provide the best, most advanced care to the communities they serve.

“Through this innovative business model, we will have a technology partner who can help us adopt the solutions that will not only help us drive operational efficiency, they will allow us to expand the type of quality care our patients have come to expect,” said Trudy Mazzone, MS, BSRT, (R), System Director, Main Line Health Cardiovascular Services and Co-director, Lankenau Heart Institute.

“By partnering with Philips, we will be able to continue our world-class cardiovascular care system-wide, including fully renovating and installing state-of-the-art Philips equipment to provide advanced cardiovascular and neuro care at Bryn Mawr Hospital and Paoli Hospital,” said William Gray, MD, System Chief, Cardiovascular Diseases, Main Line Health and Co-director, Lankenau Heart Institute. “This will allow us to define a strategy for the future, adopting novel technology as it evolves.”

This long-term strategic partnership will uniquely focus on integrated cardiovascular solutions. As part of the partnership, a dedicated team of Philips solutions architects will work collaboratively with Main Line Health to understand their challenges and develop technology plans around the cardiovascular service line. These technology plans are tailored to their needs with three objectives in mind: clinical, operational and business model innovation.

Philips brings over a century of experience in healthcare, providing best practices in world class facility planning and design, intelligent technology implementation, data analytics and IT integration, and education management, as well as workflow and performance optimization.

“Healthcare technology is evolving at a rapid rate and partnering with Main Line Health will allow us to understand patient needs and workflows, map them to the right solutions and help them to deliver on the quadruple aim,” said Vitor Rocha, Market Leader for Philips North America. “Together we can help them keep pace with technology, allowing them to focus on what is most important: providing high quality care, positive patient outcomes and a superior patient experience for their community.”

William Gray has a consulting relationship with Philips.

For further information, please contact:

Philips
Silvie Casanova
Philips North America
Tel: +1 781 879 0692
silvie.casanova@philips.com

Joost Maltha
Philips Global Press Office
Tel: +31 610 558 116
Email: joost.maltha@philips.com

Main Line Health
Samantha Krouse
Manager, Communications
Tel: +1 484 580 1059
Krouses@mlhs.org

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Lankenau Heart Institute
The Lankenau Heart Institute is Main Line Health’s premier, comprehensive cardiovascular medicine and surgery program. The Lankenau Heart Institute brings together the clinical expertise of all four Main Line Health acute care hospitals and community cardiology practices to ensure that patients receive a level of quality, service, and experience that is unprecedented in the region. Through the system-wide coordination of services, the Lankenau Heart Institute delivers preventive, diagnostic, therapeutic, and rehabilitative cardiovascular services at each of our locations including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.

Lankenau Heart Institute continues to be a pioneer in the use of beating-heart techniques and robotic-assisted procedures for coronary artery revascularization, minimally invasive and transcatheter approaches for valve repair and replacement, and complex aortic surgeries. With our growing experience and focus on minimally invasive techniques, Lankenau Heart Institute has expanded participation in clinical trials year over year. Our physicians are frequently invited to participate in clinical/medical device trials, many of these designed to facilitate minimally invasive procedures/approaches.

With a collaborative team of expert consultative cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons and specially trained nurses and technologists, the Lankenau Heart Institute is dedicated to managing and treating patients with heart failure, aortic disease, coronary and peripheral vascular disease, heart rhythm disorders and valve disease. Our team of cardiologists and cardiac specialists provide patients and their families with expert cardiac care, close to home.

About Main Line Health
Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.

At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.

Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence and the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.

Attachments